Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board
- Dr Hoekema brings over four decades of successful biotech and life science leadership
- Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO
- New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships
Southampton, UK, 2 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development. The appointments continue the strong momentum at Curve following the recent appointment of Simon Jones as CFO/COO.
